Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer

Gynecologic Oncology

Volumn 67, Issue 2, 1997, Pages 127-130

  Aghajanian, Carol ^a   Brown, Carol ^a   O'Flaherty, Catherine ^a   Fleischauer, Aaron ^a   Curtin, John ^a   Roemeling, Reinhard Von ^b   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sanofi Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; LORAZEPAM; ONDANSETRON; TIRAPAZAMINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DNA STRAND; DOSE RESPONSE; FATIGUE; FEMALE; GROWTH INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TUMOR GROWTH; UTERINE CERVIX CANCER; VOMITING;

EID: 0031282095     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4841     Document Type: Article

References (21)

1. Gray L H, Conger A D, Ebert M, Hornsey S, Scott O CA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
2. Denekamp J, Fowler J F, Dische S. The proportion of hypoxic cells in a human tumor. Int J Radiat Oncol Biol Phys. 2:1977;1227-1228.
3. Moulder J E, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 5:1987;313-341.
4. Rockwell S. Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol. 19:1992;29-40.
5. Suit H D. Modification of radiation response. Int J Radiat Oncol Biol Phys. 10:1984;101-108.
6. Gatenby R A, Coia L R, Richter M P. Oxygen tension in human tumors: in vivo mapping using CT-guided probes. Radiology. 156:1985;211-214.
7. Chaplin D J, Durand R E, Olive P L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys. 12:1986;1279-1282.
8. Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys. 20:1991;147-152.
9. Kennedy K A, Teicher B A, Rockwell S C, Sartorelli A. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol. 29:1980;1-8.
10. Vaupel P, Kallinowski F. Tissue oxygenation of primary and xenotransplanted human tumors. Radiat Res. 2:1987;707-712.
11. Baker M A, Zeman E M, Hirst V K, Brown J M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48:1988;5947-5952.
12. Cahill A, White I NH. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis. 11:1990;1407-1411.
13. Keohane A, Godden J, Stratford I J, Adams G E. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR 4233) on cell lines selected for their sensitivity to mitomycin C or ionizing radiation. Br J Cancer. 61:1990;722-726.
14. Tocher J H, Virk N S, Edwards D I. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR 4233, as a function of pH. Biochem Pharmacol. 40:1990;1405-1410.
15. Herman T S, Teicher B A, Coleman C N. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res. 50:1990;5055-5059.
16. Holden S A, Teicher B A, Ara G. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst. 84:1992;187-193.
17. Dorie M J, Brown J M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636.
18. Miller V A, Pizzo B, Grant S C, Heelan R T, von Roemeling R, Kris M G. Phase II study of tirapazamine a unique bioreductive agent, with cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 15:1996;403.
19. Rodriguez G I, Valdivieso M, Von Hoff D D, Kraut M, Burris H A, Eckardt J R, Lockwood G, Kennedy H, von Roemeling R. A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol. 15:1996;382.
20. Omura G A. Chemotherapy for cervix cancer. Semin Oncol. 21:1994;54-62.
21. Omura G A, Blessing J A, Vaccarello L, Berman M L, Clarke-Pearson D L, Mutch D G, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 15:1997;165-171.